Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.

Dalbeth N, Doyle AJ, McQueen FM, Sundy J, Baraf HS.

Arthritis Care Res (Hoboken). 2014 Jan;66(1):82-5. doi: 10.1002/acr.22059.

2.

Crystal arthritis. Intensive urate-lowering therapy improves structural joint damage in patients with tophaceous gout.

Buckland J.

Nat Rev Rheumatol. 2013 Sep;9(9):506. doi: 10.1038/nrrheum.2013.120. Epub 2013 Jul 30. No abstract available.

PMID:
23897441
3.

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA.

Arthritis Res Ther. 2013 Sep 26;15(5):R137. doi: 10.1186/ar4318.

4.

Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study.

Dalbeth N, Aati O, Kalluru R, Gamble GD, Horne A, Doyle AJ, McQueen FM.

Ann Rheum Dis. 2015 Jun;74(6):1030-6. doi: 10.1136/annrheumdis-2013-204273. Epub 2014 Feb 12.

PMID:
24521739
5.

Reversal of chronic refractory tophaceous gout with erosions with pegloticase.

Yeter KC, Ortiz EC, Arkfeld DG.

Int J Rheum Dis. 2013 Jun;16(3):369-70. doi: 10.1111/1756-185X.12073. Epub 2013 May 23. No abstract available.

PMID:
23981765
6.

Pegloticase for treating refractory chronic gout.

George RL Jr, Sundy JS.

Drugs Today (Barc). 2012 Jul;48(7):441-9. doi: 10.1358/dot.2012.48.7.1813475. Review.

PMID:
22844655
7.

Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography.

Dalbeth N, Clark B, Gregory K, Gamble G, Sheehan T, Doyle A, McQueen FM.

Ann Rheum Dis. 2009 Aug;68(8):1290-5. doi: 10.1136/ard.2008.094201. Epub 2008 Aug 15.

PMID:
18708415
8.

Relationship of bone erosion with the urate and soft tissue components of the tophus in gout: a dual energy computed tomography study.

Sapsford M, Gamble GD, Aati O, Knight J, Horne A, Doyle AJ, Dalbeth N.

Rheumatology (Oxford). 2017 Jan;56(1):129-133. doi: 10.1093/rheumatology/kew383. Epub 2016 Nov 1.

PMID:
27803304
9.

Usefulness of plain radiography for assessing hypouricemic treatment response in patients with tophaceous gout.

Suh YS, Cheon YH, Kim JE, Kim JM, Kim SH, Lee WS, Yoo WH, Lee SI, Kim HO.

Int J Rheum Dis. 2016 Nov;19(11):1183-1188. doi: 10.1111/1756-185X.12921. Epub 2016 Aug 12.

PMID:
27514938
10.

Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study.

Rajan A, Aati O, Kalluru R, Gamble GD, Horne A, Doyle AJ, McQueen FM, Dalbeth N.

Arthritis Res Ther. 2013 Oct 23;15(5):R160. doi: 10.1186/ar4343.

11.

Pegloticase and the patient with treatment-failure gout.

Dave AJ, Kelly VM, Krishnan E.

Expert Rev Clin Pharmacol. 2012 Sep;5(5):501-8. doi: 10.1586/ecp.12.48.

PMID:
23121270
12.

Evaluation and treatment of gout as a chronic disease.

Perez-Ruiz F, Herrero-Beites AM.

Adv Ther. 2012 Nov;29(11):935-46. doi: 10.1007/s12325-012-0059-z. Epub 2012 Oct 25. Review. Erratum in: Adv Ther. 2012 Dec;29(12):1067. Dosage error in article text.

PMID:
23104464
13.

Long-term safety of pegloticase in chronic gout refractory to conventional treatment.

Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, Ottery FD, Khanna D, Sundy JS.

Ann Rheum Dis. 2013 Sep 1;72(9):1469-74. doi: 10.1136/annrheumdis-2012-201795. Epub 2012 Nov 10.

14.

Factors associated with change in radiographic damage scores in gout: a prospective observational study.

Eason A, House ME, Vincent Z, Knight J, Tan P, Horne A, Gamble GD, Doyle AJ, Taylor WJ, Dalbeth N.

Ann Rheum Dis. 2016 Dec;75(12):2075-2079. doi: 10.1136/annrheumdis-2015-208937. Epub 2016 Feb 24.

PMID:
26912565
15.

Interventions for tophi in gout.

Sriranganathan MK, Vinik O, Bombardier C, Edwards CJ.

Cochrane Database Syst Rev. 2014 Oct 20;(10):CD010069. doi: 10.1002/14651858.CD010069.pub2. Review.

PMID:
25330136
16.

Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A.

Arthritis Rheum. 2002 Aug;47(4):356-60.

17.

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA.

JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169.

PMID:
21846852
18.

Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.

Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL.

J Rheumatol. 2012 Jul;39(7):1450-7. doi: 10.3899/jrheum.111375. Epub 2012 Jun 1.

19.

Pegloticase for treatment of tophaceous polyarticular gout.

Seifried RM, Roberts J.

Hawaii J Med Public Health. 2013 Jul;72(7):220-3.

20.

Update on emerging urate-lowering therapies.

Chohan S, Becker MA.

Curr Opin Rheumatol. 2009 Mar;21(2):143-9. doi: 10.1097/BOR.0b013e328325bd94. Review. Erratum in: Curr Opin Rheumatol. 2010 Jan;22(1):106.

PMID:
19339925

Supplemental Content

Support Center